|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A01N 55/02 | |
| A61K 31/555 | |||
| A61K 31/472 | |||
| A61K 31/4725 | |||
| A61K 38/13 | |||
| A61P 11/00 | |||
| A61P 17/00 | |||
| A61P 17/06 | |||
| A61P 17/14 | |||
| A61P 29/00 | |||
| A61P 19/02 | |||
| A61K 9/00 |
| (11) | Number of the document | 2265125 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09733509.5 |
| Date of filing the European patent application | 2009-04-15 | |
| (97) | Date of publication of the European application | 2010-12-29 |
| (45) | Date of publication and mention of the grant of the patent | 2019-08-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2009/002389 |
| Date | 2009-04-15 |
| (87) | Number | WO 2009/128934 |
| Date | 2009-10-22 |
| (30) | Number | Date | Country code |
| 45240 | 2008-04-15 | US |
| (72) |
BURNIER, John, US
GADEK, Thomas, US
|
| (73) |
SARcode Bioscience Inc.,
1000 Marina Blvd., Suite 250, Brisbane, CA 94005,
US
|
| (54) | TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS |
| TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS |